Ana is a molecular biologist enthusiastic about innovation and communication. In her role as a science writer she wishes to bring the advances in medical science and technology closer to the public, particularly to those most in need of them. Ana holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she focused her research on molecular biology, epigenetics and infectious diseases.
Biogen will soon launch an open-label trial to start re-dosing aducanumab — an injectable treatment under development — to patients with Alzheimer’s disease who participated in four studies halted in ... Read more
Biohaven announced that its Phase 2/3 study of the investigational oral therapy troriluzole (BHV-4157) in treating symptoms of mild to moderate Alzheimer’s disease (AD) has fully enrolled more than 700 patients. ... Read more
The second part of a clinical study evaluating the use of a blood diagnostic test for Alzheimer’s disease — called the Lymphocyte Proliferation Test (LymPro Test) — is now fully enrolled, ... Read more
Biogen is planning to seek approval for aducanumab, an injectable treatment under investigation for patients with early Alzheimer’s disease, following a new analysis of Phase 3 studies supporting meaningful benefits ... Read more
Genentech, a subsidiary of Roche, has launched a new substudy to learn more about the progression of early-onset familial Alzheimer’s disease, as part of its ongoing Alzheimer’s Prevention Initiative (API) trial ... Read more
Alzheimer’s oral therapy candidate PRI-002, being developed by Priavoid, has proven safe for human use in healthy volunteers during a Phase 1 clinical trial. These positive trial results provide important evidence ... Read more
Elenbecestat and BAN2401, two potential anti-amyloid therapies, were selected by the Alzheimer’s Clinical Trials Consortium (ACTC) to be evaluated in clinical studies aiming to prevent progression to early stages of Alzheimer’s ... Read more